BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

A COVID-19 vaccine developed by German biotech firm BioNTechand U.S. pharmaceutical giant Pfizerhas shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna , CanSino Biologicsand Inovio Pharmaceuticals .BioNTech's shares were up about 8%, after rising as much as 19% to reach their highest in more than three